https://orcid.org/0000-0002-9503-7505
References
- Takemura W, Tashiro S, Hayashi M, et al. Cefmetazole as an alternative to carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli infections based on in vitro and in vivo pharmacokinetics/pharmacodynamics experiments. Pharm Res. 2021;38(11):1839–1846. doi:10.1007/s11095-021-03140-7
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR- P. aeruginosa). Clin Infect Dis. 2021;72:1109–1116. doi:10.1093/cid/ciab295
- Ito R, Kawamura M, Sato T, Fujimura S. Cefmetazole resistance mechanism for Escherichia coli including ESBL-producing strains. Infect Drug Resist. 2022;15:5867–5878. doi:10.2147/IDR.S382142
- Utsui Y, Ohya S, Magaribuchi T, Tajima M, Yokota T. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1986;30:917–922. doi:10.1128/AAC.30.6.917
- Figueroa-Cuilan WM, Howell M, Richards C, et al. Induction of AmpC-Mediated β-Lactam resistance requires a single lytic transglycosylase in agrobacterium tumefaciens. Appl Environ Microbiol. 2022;88:1–17. doi:10.1128/aem.00333-22
- Pandey P. b -Lactam resistance in azospirillum baldaniorum Sp245 is mediated by lytic transglycosylase and b –lactamase; 2022: 1–18.